HRP20221252T1 - Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom - Google Patents

Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom Download PDF

Info

Publication number
HRP20221252T1
HRP20221252T1 HRP20221252TT HRP20221252T HRP20221252T1 HR P20221252 T1 HRP20221252 T1 HR P20221252T1 HR P20221252T T HRP20221252T T HR P20221252TT HR P20221252 T HRP20221252 T HR P20221252T HR P20221252 T1 HRP20221252 T1 HR P20221252T1
Authority
HR
Croatia
Prior art keywords
day
gemcitabine
patient
use according
bladder
Prior art date
Application number
HRP20221252TT
Other languages
English (en)
Croatian (hr)
Inventor
Dennis GIESING
Heejin Lee
Karen Daniel
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of HRP20221252T1 publication Critical patent/HRP20221252T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
HRP20221252TT 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom HRP20221252T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
EP15711373.9A EP3113782B1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
PCT/US2015/019262 WO2015134911A1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
HRP20221252T1 true HRP20221252T1 (hr) 2022-12-09

Family

ID=52697553

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20251264TT HRP20251264T1 (hr) 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
HRP20221252TT HRP20221252T1 (hr) 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20251264TT HRP20251264T1 (hr) 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom

Country Status (24)

Country Link
US (3) US20150250717A1 (enExample)
EP (2) EP3113782B1 (enExample)
JP (4) JP6901858B2 (enExample)
KR (1) KR102338079B1 (enExample)
CN (2) CN119950539A (enExample)
AU (4) AU2015226901B2 (enExample)
BR (1) BR112016020381A8 (enExample)
CA (1) CA2939979C (enExample)
DK (2) DK4124339T3 (enExample)
ES (1) ES2930435T3 (enExample)
FI (1) FI4124339T3 (enExample)
HR (2) HRP20251264T1 (enExample)
HU (1) HUE060704T2 (enExample)
IL (2) IL247347B2 (enExample)
LT (2) LT4124339T (enExample)
MX (1) MX2016011333A (enExample)
PL (2) PL4124339T3 (enExample)
PT (2) PT4124339T (enExample)
RS (2) RS67337B1 (enExample)
RU (1) RU2694902C1 (enExample)
SG (2) SG10202101978SA (enExample)
SI (1) SI4124339T1 (enExample)
SM (2) SMT202500385T1 (enExample)
WO (1) WO2015134911A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
CA2919215C (en) 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
MX2016011333A (es) * 2014-03-06 2016-12-07 Taris Biomedical Llc Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
IL262746B (en) * 2016-05-06 2022-09-01 Taris Biomedical Llc A method for treating urothelial cancer in the lower system
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
SG11202003950WA (en) * 2017-11-08 2020-05-28 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
JP2021532155A (ja) 2018-08-01 2021-11-25 タリス バイオメディカル エルエルシー トロスピウムを使用した過活動膀胱の治療方法
EP4039279A4 (en) * 2019-10-03 2023-11-01 Seikagaku Corporation TRANSMUCOSAL MEDICINAL ACTIVE DELIVERY SYSTEM FOR THE BLADDER SUBMUCOSA
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
EP4096686A4 (en) * 2020-01-27 2024-01-10 Isola Therapeutics, Inc. TISSUE DOSAGE FOR LOCAL INTRALUMINAL DRUG ADMINISTRATION
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
AU2003278881A1 (en) * 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
TW200507893A (en) * 2003-03-31 2005-03-01 Alza Corp Osmotic pump with means for dissipating internal pressure
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
MX348005B (es) 2007-12-11 2017-05-23 Massachusetts Inst Technology Dispositivo implantable de liberación de fármacos y métodos para tratar la vejiga y otras vesículas o lúmenes corporales.
CA2733468C (en) 2008-08-09 2017-12-05 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
JP5913095B2 (ja) 2009-06-26 2016-04-27 タリス バイオメディカル エルエルシー 植込み型薬物送達装置及びその作製方法
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP3884988B1 (en) 2009-12-17 2025-06-18 TARIS Biomedical LLC Implantable device with intravesical tolerability
EP2525777B1 (en) * 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material and method for treating internal cavities
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
US8690840B2 (en) 2010-10-06 2014-04-08 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
CA2825399A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
MX367070B (es) * 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
CA2902556C (en) 2013-03-15 2021-06-22 Heejin Lee Drug delivery devices and methods for drug delivery
JP6517186B2 (ja) * 2013-03-15 2019-05-22 タリス バイオメディカル エルエルシー 薬物透過性構成部材を備えた薬物送達デバイス、及び方法
CA2919215C (en) * 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
WO2015069723A1 (en) * 2013-11-05 2015-05-14 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
MX2016011333A (es) * 2014-03-06 2016-12-07 Taris Biomedical Llc Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.

Also Published As

Publication number Publication date
US20220347091A1 (en) 2022-11-03
JP2017508749A (ja) 2017-03-30
KR20160124425A (ko) 2016-10-27
SMT202500385T1 (it) 2025-11-10
SG11201607342QA (en) 2016-10-28
ES2930435T3 (es) 2022-12-13
BR112016020381A2 (pt) 2017-08-15
AU2015226901B2 (en) 2020-05-14
MX2016011333A (es) 2016-12-07
RS63675B1 (sr) 2022-11-30
JP7061595B2 (ja) 2022-04-28
JP2024009034A (ja) 2024-01-19
AU2024259822A1 (en) 2024-11-28
US20150250717A1 (en) 2015-09-10
EP3113782A1 (en) 2017-01-11
WO2015134911A1 (en) 2015-09-11
CN106102751A (zh) 2016-11-09
AU2020217383A1 (en) 2020-09-03
IL247347B2 (en) 2025-03-01
BR112016020381A8 (pt) 2018-05-02
AU2020217383B2 (en) 2022-09-08
JP6901858B2 (ja) 2021-07-14
EP4124339A1 (en) 2023-02-01
HUE060704T2 (hu) 2023-04-28
US20220117886A1 (en) 2022-04-21
JP2022022235A (ja) 2022-02-03
CN119950539A (zh) 2025-05-09
IL311410A (en) 2024-05-01
HRP20251264T1 (hr) 2025-12-05
NZ723303A (en) 2023-10-27
IL311410B2 (en) 2025-11-01
IL247347B1 (en) 2024-11-01
AU2015226901A1 (en) 2016-09-01
LT3113782T (lt) 2022-11-25
DK4124339T3 (da) 2025-10-13
JP7383681B2 (ja) 2023-11-20
PT3113782T (pt) 2023-01-05
PL4124339T3 (pl) 2025-11-17
SI4124339T1 (sl) 2025-11-28
SG10202101978SA (en) 2021-04-29
EP4124339B1 (en) 2025-09-10
SMT202200449T1 (it) 2023-01-13
LT4124339T (lt) 2025-11-10
RU2694902C1 (ru) 2019-07-18
AU2022215156B2 (en) 2024-09-05
RS67337B1 (sr) 2025-11-28
JP2019218410A (ja) 2019-12-26
EP3113782B1 (en) 2022-09-28
AU2022215156A1 (en) 2022-09-01
DK3113782T3 (da) 2022-10-17
PL3113782T3 (pl) 2023-01-23
CA2939979C (en) 2023-03-21
CA2939979A1 (en) 2015-09-11
IL247347A0 (en) 2016-11-30
FI4124339T3 (fi) 2025-10-17
KR102338079B1 (ko) 2021-12-09
PT4124339T (pt) 2025-11-04
IL311410B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
HRP20221252T1 (hr) Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom
HRP20211921T1 (hr) Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s oksaliplatinom
JP2017508749A5 (enExample)
BR112015005351A2 (pt) sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
MX2024000737A (es) Sistema de administracion, dispositivo de suministro, y dispositivo de notificacion para comunicar el estado de un dispositivo medico.
FI3922279T3 (fi) Lääkkeenantokoostumuksia ja niiden käyttötapoja
Dhowan et al. Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose
RU2015109298A (ru) Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина
BR112017012706A2 (pt) formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BR112015022067A2 (pt) método e aparato para a administração de droga a um sítio alvo
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
MX2019014942A (es) Dispositivos de administracion de farmacos bioerosionables.
MX2018004695A (es) Composiciones de proteinas estables.
NZ769954A (en) Syringe devices for use in an emergency
BR112018000039A2 (pt) dispositivo de liberação de uso único
HRP20200879T1 (hr) Medicinski aplikator
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
AR096223A1 (es) Pastilla de nicotina para administración oral
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas